Fra Novo Nordisk:
Novo Nordisk raises sales and operating profit outlook for 2020
Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.
In the third quarter of 2020, Novo Nordisk’s sales increased by 7% and operating profit increased by 7%, both at CER. This reflects lower than anticipated negative impacts from COVID-19 as well as underlying market demand. Sales growth was positively impacted by inventory changes at wholesaler level in the US.
| Profit and Loss (CER) | First nine months 2020 | Third quarter 2020 |
| Net sales growth | 7% | 7% |
| Operating profit growth | 7% | 7% |
Following lower than anticipated negative COVID-19 impacts and underlying market demand, full-year outlook is increased for sales and operating profit, both at CER.
| Outlook 2020 (CER) | Expectations 8 October | Expectations 6 August |
| Sales growth | 5-8% | 3-6% |
| Operating profit growth | 5-8% | 2-5% |
Novo Nordisk’s full disclosure of the financial results for the first nine months of 2020 will be published on 30 October 2020.
The outlook is based on a number of assumptions related to the severity and duration of impacts from COVID-19. In addition, the above expectations are based on assumptions which are further described on pages 15 and 16 of the Financial Report for the period 1 January 2020 to 30 June 2020 (Company Announcement No 49 / 2020) including that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during the remainder of 2020.
The forward-looking statements on page 21 of the Financial Report for the period 1 January 2020 to 30 June 2020 (Company Announcement No 49 / 2020) also apply to this company announcement.
Conference call to be held on 9 October 2020 at 08.30 CEST
On 9 October 2020 at 08.30 CEST, corresponding to 2.30 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’. During a 30 minutes call, representatives from Novo Nordisk will elaborate on the changed 2020 outlook and host a Q&A session.
